FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump
This article was originally published in Scrip
Executive Summary
Neon Therapeutics launched its immunotherapy platform with $55m in Series A venture capital, exceeding recent investments in several other private therapeutics companies, including a diabetes drug developer on its fifth round of funding.